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Introduction: Literature concerning primary pulmonary sarcomas 
(PPS) is limited to small case series. This study examines, in a large 
cohort, the clinical characteristics and therapeutic strategies of PPS 
and their impact on overall survival (OS).
Methods: This was a retrospective analysis from the Surveillance, 
Epidemiology, and End Results database (1988–2008). Eligible 
patients had primary PPS and underwent local therapy. Survival esti-
mates were obtained using the Kaplan–Meier method and the Cox 
regression model. OS of PPS patients were compared with a cohort 
of 10,909 patients with extremity soft-tissue sarcomas.
Results: The cohort included 365 PPS patients with a median fol-
low-up of 21 months. Fifty-five percent of the patients had large 
tumors (>5 cm), 76% were high-grade, and 16% had node-positive 
disease. Seventy-five percent of the cohort underwent surgery alone, 
14% underwent surgery and radiation therapy, and 11% underwent 
radiation therapy alone. Multivariate analysis showed reduced OS for 
patients with tumors more than 5 cm (hazard ratio [HR] 1.6, 95% 
confidence interval [CI] 1.25–2.19), high tumor grade (HR 3.1, 95% 
CI 1.26–3.62), and unresectable disease (HR 2.6, 95% CI 1.76–3.88. 
The 5-year OS for the cohort of pulmonary sarcomas versus sarco-
mas of the extremities was 35% versus 71% (p < 0.0001).
Conclusion: This large study examining PPS patients reveals a high 
rate of nodal involvement and a markedly worse OS than patients 
with extremity soft-tissue sarcomas. Thus, given the poor overall 
prognosis, it is recommended that PPS patients undergo a thorough 
mediastinal nodal evaluation to rule out locoregional metastasis and 
proceed with aggressive treatment.
Key Words: Pulmonary, Sarcoma, Survival, Surveillance, 
Epidemiology, and End Results.
(J Thorac Oncol. 2013;8: 147–151)
Primary pulmonary sarcomas (PPS) represent a rare tumor type.1–6 Existing literature regarding PPS has been lim-
ited only to small retrospective case series that have exam-
ined the impact of tumor pathology and clinical management 
strategies on overall survival (OS). However, interpretation 
of these results has been severely limited by the small sample 
sizes.6,7
Several reports demonstrate a survival benefit associ-
ated with surgical resection.7,8 Yet, there are conflicting data 
about which patient and tumor characteristics have prognostic 
value.7–13 
The purpose of this study is to examine a large cohort of 
PPS patients to better characterize the pathologic and clinical 
features of PPS that impact survival. Furthermore, survival in 
PPS patients was compared with survival in patients with soft-
tissue sarcomas of the extremity.
PATIENTS AND METHODS
The Surveillance, Epidemiology, and End Results 
(SEER) database of the National Cancer Institute collects 
incidence and survival data from 17 population-based cancer 
registries covering 28% of the U.S. population. The SEER pro-
gram registries collect data on patient demographics, primary 
tumor site and morphology, stage at diagnosis, first course of 
treatment, and follow-up for vital status.
Eligible patients had histologically confirmed invasive 
soft tissue sarcoma of the lung, bronchus, carina, or hilum with 
no known metastasis. Patients were identified using site codes 
C340-C349 of the International Classification of Diseases for 
Oncology, third edition. Analysis was restricted to patients 
aged 20 years and older, who were diagnosed between 1988 
and 2008, and underwent surgery, radiation therapy (RT), 
or both. Detailed information regarding the tumor size and 
grade were available in the SEER database only after 1988. 
Patients with Kaposi’s sarcoma were excluded because the 
majority of these patients have acquired immunodeficiency 
syndrome, which would confound survival outcomes. Patients 
with rhabdomyosarcoma, Ewing’s sarcoma, Askin tumor of 
soft tissue, peripheral neurectodermal tumor of soft tissue, 
and extrarenal rhabdoid tumor were also excluded from 
the analysis because the primary treatment of these tumors 
includes chemotherapy, which is not coded in the database. 
The total sample included 365 patients.
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Variables
OS was the primary study endpoint. This was defined as 
the time from diagnosis to death. Variables included whether 
patients received surgery alone, external beam RT alone, or 
both. Exact detail regarding the use of adjuvant chemotherapy 
and specific RT technique (i.e. dose, fraction, beam energy) 
was not available in the SEER database.
Covariates included in the analysis were all categori-
cal and included: age (20–44, 45–59, 60–74, and 75+ years), 
sex, SEER registry location, year of diagnosis, T classification 
(T1 < 5 cm, T2 > 5 cm), node (N) classification, grade (low 
grade = 1–2, high grade = 3–4), laterality, and histology. 
Detailed information regarding the margin status at the time 
of resection, local control, and performance status is not avail-
able in the SEER database.
Statistical Analysis
All data were analyzed using R (version 2.13). Pearson’s 
χ2 tests were used to analyze the frequency distribution of the 
categorical variables. Estimates of OS were calculated using 
the Kaplan–Meier method as a function on size, grade, and 
nodal status. Survival was also calculated for patients who 
underwent surgery alone, RT alone, or both. The log-rank test 
was used to determine whether differences in survival curves 
were statistically significant.
To determine independent predictors of overall mortal-
ity, hazard ratios (HR) and their 95% confidence intervals (CI) 
were calculated using multivariable Cox proportional hazards 
models adjusted for all covariates of interest. The models 
were run for the full sample of patients using the covariates 
that were found to be significant in the univariate analysis. 
Furthermore, we compared the OS of pulmonary sarcomas 
with that of extremity soft-tissue sarcomas. All results were 
considered significant when p was less than 0.05.
RESULTS
This study examined a total of 365 patients with a 
median follow-up of 21 months (range, 1 month–20 years). 
Patient and clinical characteristics of the cohort are depicted 
in Table 1. The median age was 63 years (range, 20–85 years). 
Fifty-five percent of the cohort had tumors greater than 5 cm, 
and more than 40% were high-grade. Furthermore, 16% had 
node-positive disease. There was no correlation between his-
tologic subtype and nodal status. Approximately 75% of the 
cohort underwent surgery alone and the remaining patients 
received RT alone or both surgery and RT. The most fre-
quently identified histologies were fibroblastic and myofibro-
blastic tumors (16.2%).
Univariate Analysis
Among those with pulmonary sarcomas, the 5-year OS 
was 48% for tumors less than 5 cm and 25% for tumors greater 
than 5 cm (p < 0.0001). The 5-year OS for patients with 
low- and high-grade tumors was 73% and 23%, respectively 
(p < 0.0001, Fig. 1). The 5-year OS for patients with node-
negative disease was 39%, whereas it was 14% for those with 
node-positive disease (p < 0.0001, Fig. 2).
TABLE 1.  Patient and Tumor Characteristics 
Variable No. of Cases (%)
Age (yr)
20–44 53 (15)
44–59 93 (26)
59–75 129 (35)
75+ 90 (25)
Sex
Male 203 (56)
Female 162 (44)
Registry location
California (excluding LA, SF, SJ) 66 (18)
Los Angeles 43 (12)
Seattle 39 (11)
New Jersey 36 (10)
San Francisco 29 (8)
Connecticut 28 (8)
Iowa 25 (7)
Detroit 23 (6)
Kentucky 16 (4)
Atlanta 13 (4)
Utah 11 (3)
Louisiana 11 (3)
San Jose 10 (3)
Hawaii 9 (3)
New Mexico 6 (2)
Georgia (excluding Atlanta) 0 (0)
Alaska 0 (0)
Race
White 327 (90)
Black 16 (4)
American Indian, Asian, Alaska
Native/Pacific Islander 20 (5)
Unknown 2 (1)
Year of diagnosis
1988 5 (1)
1989 7 (2)
1990 4 (1)
1991 11 (3)
1992 10 (3)
1993 11 (3)
1994 6 (2)
1995 12 (3)
1996 13 (4)
1997 13 (4)
1998 19 (5)
1999 11 (3)
2000 25 (7)
2001 33 (9)
2002 27 (7)
2003 32 (9)
2004 26 (7)
(Continued)
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Regarding therapy, the 5-year OS was 41% for those 
who underwent surgery alone, 25% for those who underwent 
surgery and RT, and 7% for those who underwent radiation 
alone (p < 0.0001, Fig. 3). On subset analysis, those who 
received adjuvant RT were more likely to have tumors greater 
than 5 cm (65% versus 51%), high-grade tumors (94% versus 
70%), and node-positive disease (27% versus 10%).
The 5-year OS for the cohort of pulmonary sarcomas 
compared with soft-tissue sarcomas of the extremities was 
35% versus 71%, respectively (p < 0.0001). In relation to 
clinical characteristics, T-stage was similar between extrem-
ity and pulmonary sarcomas. Pulmonary sarcomas did have 
a significantly larger proportion that were node-positive (16% 
versus 1%), and high-grade (76% versus 54%) compared with 
extremity soft-tissue sarcomas (p < 0.05). Regarding histology, 
there were a significantly higher proportion of fibrous tumors 
(33% versus 8%) and liposarcomas (25% versus 1%) in the 
extremity sarcomas versus the pulmonary sarcomas (p < 0.05).
Multivariate Analysis
Patient age, tumor size, tumor grade, and treatment type 
significantly affected OS on multivariate analysis as shown in 
TABLE 1. (Continued )
Variable No. of Cases (%)
2005 28 (8)
2006 29 (8)
2007 22 (6)
2008 21 (6)
Tumor size (cm)a
0–4.99 152 (43)
5+ 201 (57)
Diffuse 1 (<1)
Gradea
Low (1–2) 50 (24)
High (3–4) 161 (76)
Node Status
Node-negative 307 (84)
Node-positive 58 (16)
Histologic type
Unspecified soft tissue sarcomas 131 (36)
Fibroblastic and myofibroblastic tumors 59 (16)
Leiomyosarcoma 53 (15)
Synovial sarcomas 43 (12)
Fibrohistiocytic tumors 30 (8)
Blood vessel tumors 21 (6)
Nerve sheath tumors 15 (4)
Miscellaneous soft tissue sarcomas 7 (2)
Liposarcoma 2 (<1)
Osseous and chondromatous neoplasms of soft tissue 2 (<1)
Other fibromatous tumors 1 (<1)
Alveolar soft parts sarcoma 1 (<1)
Laterality
Right 179 (49)
Left 183 (51)
Therapy type
Surgery alone 274 (75)
Radiation therapy alone 39 (11
Surgery + radiation therapy 52 (14)
aDoes not include unknown cases.
LA, Los Angeles; SF, San Francisco; SJ, San Jose.
FIGURE 1.  Percentage overall survival is depicted for tumors 
of small (<5 cm) and large (>5 cm) size. Patients with tumors 
of unknown size are excluded (n = 353).
FIGURE 2.  Percentage overall survival is depicted for low-
grade (grade 1 or 2) and high-grade (grade 3 or 4) tumors. 
Patients with tumors of unknown grade are excluded (n = 211).
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Table 2. The estimated HR was 2.6 (95% CI 1.76–3.88) for 
those with unresectable disease, 1.3 (95% CI 0.94–1.96) for 
the surgery+RT group, and 1.0 (reference) for the surgery-
alone group. High tumor grade was associated with reduced 
OS compared with low tumor grade (HR 3.14, 95% CI 1.26–
3.62). There was also a trend toward reduced OS for patients 
with node-positive disease compared with node-negative dis-
ease (HR 1.37, 95% CI 0.97–1.94).
DISCUSSION
This is the first large, population-based cohort study to 
examine patient-specific clinical characteristics and various 
treatment strategies and their concomitant relationship to OS 
in patients with primary sarcoma of the lung.
PPS are rare tumors and this study examined the impact 
of tumor and clinical characteristics on survival. Earlier stud-
ies examining PPS have suggested that large tumor size and 
high tumor grade represent negative prognostic factors,13 
though other case series have not replicated these findings.7,9,11 
This study demonstrates, over a substantially larger cohort, 
that large size (> 5 cm) and high grade are associated with 
a significantly worse OS. These findings are consistent with 
other large series that have examined these factors in soft-
tissue sarcomas of the extremities.14–18
Earlier studies show that patients able to undergo 
complete surgical resection have significantly improved 
survival compared with patients with unresectable tumors 
or positive surgical margins.7,8,19 These findings confirm 
results of an improved survival seen in those who are able 
to undergo resection. Although significantly worse clinical 
characteristics made up the subgroup of patients who 
underwent surgery and RT, the multivariate analysis shows 
that their OS was not statistically different from that of those 
who received surgery alone. This may reflect a survival 
benefit gained from improved locoregional control through 
the use of adjuvant RT.
This study also demonstrates important prognostic 
differences between PPS and primary soft-tissue sarcomas 
of the extremity. PPS had a significantly worse 5-year OS 
compared with extremity soft tissue sarcomas (35% versus 
71%, p < 0.001). It is noteworthy that 16% of PPS in this 
cohort had node-positive disease whereas past studies show 
that only 2% to 6% of patients with extremity soft-tissue sar-
comas have node-positive disease.20–22 This discrepancy is 
FIGURE 3.  Percentage overall survival is depicted for 
patients who received surgery alone, surgery plus radiation 
therapy, and radiation therapy alone.
TABLE 2.  Hazard Ratios and 95% Confidence Intervals for 
Multivariable Models of Overall Mortality 
Variable HR 95% CI
Age (yr)
20–44 1 Reference
44–59 1.53 (0.92, 2.56)
59–75 2.34 (1.47, 3.75)
75+ 3.29 (2.03, 5.34)
Sex
Male 1 Reference
Female 0.86 (0.66, 1.12)
Tumor size (cm)
0–4.99 1 Reference
5+ 1.66 (1.25, 2.19)
Grade
Low (1–2) 1 Reference
High (3–4) 3.14 (1.85, 5.31)
Unknown 2.14 (1.26, 3.62)
Node status
Node-negative 1 Reference
Node-positive 1.37 (0.97, 1.94)
Therapy type
Surgery alone 1 Reference
Radiation therapy alone 2.62 (1.76, 3.88)
Surgery + radiation therapy 1.35 (0.94, 1.96)
TABLE 3.  Selected Studies Investigating Primary Pulmonary 
Sarcoma 
Authors N
Mean Age at  
Diagnosis (yr)  
(Range)
5-Year  
Survival 
(%)
Janssen et al. 199413 22 49.5 (5–76) 44
Bacha et al. 19997a 23 51 (20–78) 69
Régnard 19998a 24 48 (14–73) 48
Porte 200011 18 50 (19–73) 43
Etienne-Mastroianni  
et al. 20029
12 53 (16–93) 38
Petrov 200312 48 53.3 (13–78) 48
Current study 365 62 (20–85) 41
aFive-year survival reported for patients undergoing tumor resection.
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likely multifactorial, involving contributions from underly-
ing genetic predispositions for metastasis and differing lym-
phatic drainage patterns. These results support the routine 
use of a thorough mediastinal nodal evaluation with posi-
tron emission tomography, mediastinoscopy, or mediastinal 
nodal dissection at the time of resection to rule out locore-
gional metastatasis. Given the high rate of nodal metastasis 
and poor prognosis, pulmonary sarcoma patients should be 
treated aggressively. These data do suggest that patients may 
benefit from combined surgery and radiotherapy. Likewise, 
these patients should be considered for chemotherapy when 
appropriate. These patients might derive a greater potential 
benefit from systemic chemotherapy than the 5% OS benefit 
seen with adjuvant chemotherapy in patients with soft-tissue 
sarcomas of the extremity.23 The relatively poor survival seen 
in the node-positive cohort suggests that this group may ben-
efit from neoadjuvant chemoradiation followed by surgical 
resection in an effort to maximize local control, similar to a 
treatment strategy that is often used in locally advanced lung 
cancer.
This study was limited by information that was either 
not available or not reported in the SEER database. More than 
one third of cases in this study were classified as a primary 
sarcoma that is not otherwise specified. This likely reflects 
the difficulty in the tissue diagnosis of PPS, which has been 
discussed extensively by Etienne-Mastroianni et al.9 Rapidly 
advancing diagnostic techniques may allow future studies to 
further characterize the relationship between PPS histology 
and behavior. Although this study adjusted for all available 
patient and tumor characteristics, there are unreported patient 
factors that could potentially confound the analysis, such as 
tumor margin status or patient performance status. Another 
limitation is that in patients who did not undergo surgery, the 
nodal staging was based on clinical criteria (American Joint 
Committee on Cancer tumor, node, metastasis staging crite-
ria), and thus may have been less accurate than in those who 
underwent surgical resection and had pathologic examination 
of the resected lymph nodes. Moreover, the SEER database 
contains no detailed information regarding radiation tech-
nique (total dose, fraction size, beam energy) or chemother-
apy protocols.
In conclusion, this large study examining PPS revealed 
that these patients have a markedly worse OS than patients 
with extremity soft-tissue sarcomas. Furthermore, PPSs are 
associated with a higher rate of nodal metastasis relative to 
soft-tissue extremity sarcomas. Thus, it is recommended that 
pulmonary sarcoma patients undergo a thorough mediastinal 
nodal evaluation to rule out locoregional metastasis. Given 
their poor overall prognosis, it is recommended that these 
patients be treated aggressively.
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